Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Karyopharm Therapeutics Inc maintains a gross margin of 95.65%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -52.36%, while the net margin is -299.89%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively KPTI converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, KPTI competes directly with industry leaders such as TLSA and SGMT. With a market capitalization of $175.92M, it holds a significant position in the sector. When comparing efficiency, KPTI's gross margin of 95.65% stands against TLSA's N/A and SGMT's N/A. Such benchmarking helps identify whether Karyopharm Therapeutics Inc is trading at a premium or discount relative to its financial performance.
